Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic...

Area of Science:

• Critical Care Medicine
• Hepatology
• Renal Medicine

Background:

• Critically ill patients face risks of acute liver dysfunction as part of multiorgan failure.
• Hemoadsorption aims to clear blood toxins, potentially preventing further organ damage.
• Current evidence on hemoadsorption efficacy for liver dysfunction is limited.

Purpose of the Study:

• To systematically review and perform a meta-analysis on clinical outcomes of hemoadsorption therapy in critically ill patients with liver dysfunction.
• To assess the safety and efficacy of hemoadsorption in improving liver function and related parameters.

Main Methods:

• Systematic literature search across six databases (PROSPERO registration: CRD42022286213) from 2011-2023.
• Included 30 publications involving 335 patients with liver dysfunction due to critical illness.
• Analyzed case presentations, observational studies, and registry data.

Main Results:

• Individual case analysis showed significant reductions in aspartate transaminase and vasopressor needs (p=0.03).
• A trend towards lower total bilirubin, alanine transaminase, C-reactive protein, and creatinine was observed.
• Pooled data revealed a significant reduction in total bilirubin (mean difference -4.79 mg/dL, p=0.002).

Conclusions:

• Hemoadsorption appears safe for critically ill patients with acute liver dysfunction.
• The therapy shows a trend towards improved liver function post-treatment.
• High-quality evidence is crucial to definitively establish the clinical benefits of hemoadsorption.